Kornimate/medical-research-clean huggingface dataset:
advanced cognitive stimulation therapy hong kong (acst-hk)

Conditions: Dementia; Dementia, Vascular; Dementia, Mixed; Dementia With Lewy Bodies; Dementia Frontal; Dementia Severe; Dementia Moderate; Dementia of Alzheimer Type

Summary: this study is a feasibility randomized controlled trial (rct) for an evidence-based intervention for people with moderate to severe dementia in hong kong. the psychosocial intervention is adapted from cognitive stimulation therapy (cst), translated and adapted for the hong kong chinese population, and developed within the medical research council (mrc) framework.

the world health organization calls for an increase of psychosocial interventions for dementia-a global epidemic. cognitive stimulation therapy (cst) is the only non-pharmacological therapy recommended by the national institute for health and care excellence for improving cognition for mild to moderate dementia. however, there is little guidance on how to maximise cognition for severe dementia. advanced cognitive stimulation therapy (acst) will be the first evidence-based complex intervention for moderate to severe dementia developed within the medical research framework and building upon cst's key principles. this feasibility randomised controlled trial (rct) aims to 1) translate and adapt acst for the chinese population; 3) evaluate the feasibility of advanced cognitive stimulation therapy - hong kong (acst-hk). a sample of 32 participants will be recruited, where 16 will be randomly allocated to acst, and 16 to treatment as usual (tau). data will be collected pre and post the 7-week intervention period. improving the cognition and qol for people with moderate to severe dementia is vital because dementia's prevalence is projected to reach 152 million by 2050, resulting in excessive excess disability. developing an intervention targeting chinese-the largest aging population-is also novel and allows acst-hk to impact internationally from its infancy.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 2. diagnosis of dementia, according to the dsm-v 3. cmmse ≤ 12 4. ability to communicate in english 5. ability to complete outcome measures 6. not having major physical illness or disability that affects participation 7. consultee willing and able to provide written informed consent, if participant is not able to provide consent. 8. ability to remain in a group for around an hour (e.g. no challenging behaviour) exclusion criteria: 1. illness and disability that affects participation (as deemed by researcher or attending 2. care home staff) 3. cmmse \< 5 4. participation in other psychosocial intervention studies

Keywords: dementia randomized controlled trial cognitive stimulation moderate to severe dementia
ambrisentan (letairis) for sarcoidosis associated pulmonary hypertension

Conditions: Sarcoidosis; Pulmonary Hypertension

Summary: hypothesis: ambrisentan (letairis ®) is safe and effective in treating pulmonary hypertension in patients with sarcoidosis

primary endpoint: change in 6 minute walk distance.

Eligibility criteria:
inclusion criteria: * biopsy proven sarcoidosis * mean pulmonary artery pressure \> 25 mmhg at rest and greater than 30 mmhg with exercise by right heart catheterization within 1 year prior to entry into study * pulmonary capillary wedge pressure ≤ 15 mmhg * pvr values \>3.0 woods units * forced vital capacity (fvc) \>40% * who functional class ii or iii * stable sarcoidosis treatment regimen for three months prior to entry into study * 6 minute walk distance between 150-450 meters * stable dose of antihypertensive medications * on no other medication to treat pah (sildenafil, tadalafil, vardenafil, treprostinil, epoprostenol, iloprost, bosentan, sitaxsentan) within one month prior to enrollment and during duration of the study * non-pregnant females exclusion criteria: * exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis) * severe systemic hypertension \> 170/95 * patients with congestive heart failure (left ventricular dysfunction) or primary right ventricular dysfunction * anticipation by the investigator for escalation in sarcoidosis treatment during the course of the study * pulmonary hypertension related to etiology other than sarcoidosis (i.e. hiv, scleroderma, etc.) * use within 1 month of an endothelin receptor antagonists (bosentan, sitaxsentan). * who functional class iv status * patients with significant left ventricular dysfunction * significant liver dysfunction not due to sarcoidosis. * patients with severe other organ disease felt by investigators to impact on survival during the course of the study.

Keywords: sarcoidosis pulmonary hypertension dyspnea sarcoidosis associated pulmonary hypertension
immunotherapy for peanut allergy

Conditions: Allergy

Summary: currently, when a food allergy is diagnosed, the "standard of care" is strict avoidance of the allergic food and ready access to self-injectable epinephrine. yet, accidental ingestions do occur. unfortunately, for a ubiquitous food such as peanut, the possibility of an inadvertent ingestion is great. it is estimated that over 50% of individuals who are allergic to peanuts will have an accidental reaction to peanuts over a 2-year period. the purpose of this study is to determine if peanut sublingual immunotherapy (slit) reduces the number and/or symptoms of accidental peanut ingestion in peanut allergic subjects. we would anticipate that the subjects on the peanut slit protocol would experience few adverse effects with accidental peanut ingestion over the course of the two years of slit. the primary endpoint to evaluate the effectiveness of slit will be a negative dbpcfc to peanuts (8 grams) at the completion of the two years of the study.

peanut allergy is one of the most serious of the immediate hypersensitivity reactions to foods in terms of persistence and severity of the reaction and appears to be a growing problem. allergen-specific immunotherapy (it) is currently being examined as a treatment option because of the persistence of this hypersensitivity reaction and the lack of effective treatment. an understanding of the molecular mechanisms of peanut-specific it is vital to ensure the eventual, successful treatment of peanut-allergic patients. the goal of this proposal is to develop peanut immunotherapy (it) for patients with peanut allergic reactions. this innovative application is designed to utilize the extensive knowledge of the allergens involved in peanut hypersensitivity to devise an immunotherapeutic approach that would lower the risk of anaphylactic reactions and would down regulate peanut-specific t cells in peanut-allergic patients. previous attempts to utilize peanut-specific immunotherapy have been unsuccessful primarily because of the severe side effects of therapy. the specific aim of the study is to desensitize/tolerize peanut-allergic subjects with peanut allergen-specific, sublingual immunotherapy (slit) and begin to determine the molecular mechanism of the peanut-specific t-cell response during slit. the hypothesis is that peanut slit will desensitize patients with peanut allergic reactions by the induction of peanut specific regulatory t cells resulting in immune modulation of the peanut allergic reaction.

Eligibility criteria:
inclusion criteria: * subjects between 6 and 35 years of age * diagnosed with peanut allergy by positive prick skin test, cap feia of 15 ku/l or greater * history of significant clinical symptoms within one hour after ingestion of peanuts * family's compliance with all study visits exclusion criteria: * subjects with medical history preventing a bdpcfc to peanut * subjects unable to cooperate with challenge procedure * subjects unable to be reached by telephone for follow-up * subjects with a history of severe anaphylaxis to peanut

Keywords: peanut allergy
impact of personality on satisfaction following presbyopic correction

Conditions: Personality; Patient Satisfaction; Presbyopia

Summary: primary objective of this study is the exploration of the impact of personality type, social roles and working mandates οn the visual capacity and satisfaction of patients that underwent pseudophakic presbyopic correction.

personality type, social types and working mandates will be evaluated as a routine procedure to patients that visit the presbyopia service of the university hospital of alexandroupolis, by means of structured questionnaires. six months following pseudophakic presbyopic correction surgery, each study participant will be evaluated for his/her visual capacity and vision-specific quality of life. regression modeling will be attempted in order to identify the exact demographics, social roles and personality type of the patient that is most compatible to receive pseudophakic presbyopic correction.

Eligibility criteria:
inclusion criteria: * presbyopia, patients of our outpatient ophthalmology clinic, age between 40 and 85 years exclusion criteria: * inability to cooperate, former diagnosis of mental disease

Keywords: multifocal presbyopic correction personality traits vision oriented quality of life
inhaled corticosteroids for the treatment of transient tachypnea of the newborn

Conditions: Transient Tachypnea of the Newborn

Summary: transient tachypnea of the newborn (ttn) is a common respiratory disorder affecting late preterm and term babies caused by lung edema resulting from delayed absorption of fetal alveolar lung fluid. the investigators hypothesize that enac expression will be up-regulated as a result of administration of corticosteroids. this effect will lead to enhanced absorption of fetal lung fluid finally treating ttn. the aim of our study will be to evaluate whether inhaled corticosteroids reduce respiratory distress and morbidity in late preterm and term neonates presenting with ttn.

the primary outcome measure will be the assessment of respiratory distress reflected by ttn clinical score in neonates presenting with ttn and treated with inhaled corticosteroids compared to placebo.

Eligibility criteria:
inclusion criteria: * late preterm and term infants (post-menstrual age ≥ 34 weeks) delivered by cesarean section or vaginal delivery * diagnosis of ttn * parents signed informed consent exclusion criteria: * meconium aspiration syndrome * respiratory distress syndrome * congenital heart disease * non respiratory disorders causing tachypnea

Keywords: ttn
efficacy of lyophilized food extracts for skin prick tests and atopy patch test at different storage time

Conditions: Food Allergy

Summary: comparison the result of skin prick tests and atopy patch test of lyophilized food extracts at different storage time (0, 3 and 6 months) after preparation

skin prick test were performed with lyophilized food extracts (cow milk, egg white, egg yolk, wheat, soy and shrimp) at different storage time (0, 3 and 6 months) after preparation. atopy patch test were performed with lyophilized food extracts (cow milk, egg white, egg yolk, wheat, soy and shrimp) at different storage time (0, 3 and 6 months) after preparation

Eligibility criteria:
inclusion criteria: * mild to moderately severe food allergy patients * at least positive skin test to one kind of common food (commercial extract) * stop antihistamine or corticosteroid (if more than 20mg/day) for at least 7 days exclusion criteria: * dermographism * severe systemic disease such as autoimmune disease, immune deficiency, malignancy * severe dermatitis or large area involment * pregnancy
topical treatments for ankle sprains

Conditions: Ankle Sprain

Summary: our aim was to evaluate the effects of topical analgesic drugs on rapid recovery of joint functions and pain relief in acute ankle injuries. a total of 100 patients were included in the study and divided into 2 groups as diclofenac and etofenamate. the pain scores of the patients were evaluated with the numeric rating scale and wong-baker scale before and after treatment. dorsiflexion and plantarflexion active joint movements were measured with a hand-held goniometer for joint function before and after treatment. we found that ankle sprains were more common in men. in our study, we found that both topical analgesics were effective in improving joint movements and reducing pain.


Eligibility criteria:
inclusion criteria:those over the age of 18, who applied to the emergency room within the first 48 hours after an ankle sprain, who have grade 1/mild and grade 2/moderate ankle sprains, who have excluded fractures and dislocations, who have no muscle-tendon ruptures, no vascular or nerve injuries, no open wounds or burns, whose vital signs are stable, and who give written and verbal consent. - exclusion criteria:those who did not present within the first 48 hours of ankle sprain, grade 3/severe ankle sprain, multiple trauma, pregnancy, suspected pregnancy, foot and ankle fractures and dislocations, those who had a previous ankle operation or fracture, and cases who did not accept to participate in the study -

Keywords: local anesthesia emergency nonsteroidal anti-inflammatory drug ankle sprain
impacts of the 10 steps for healthy feeding in infants: a randomized field trial

Conditions: Anemia; Breast Feeding, Exclusive; Overweight and Obesity

Summary: this study assesses the effectiveness of a nutrition advice programme - the ten steps for healthy feeding of children under two years old - on nutritional status, diet, and morbidity history of children. this is a randomized controlled trial in mostly socioeconomic deprived families (intervention=200; controls=300). mothers of the intervention group received dietary counseling in the first year of life. both groups received routine care by their paediatricians and research assessment at 6 and 12 months, 4 years, 8 years and 12 years of age.


Eligibility criteria:
inclusion criteria: * newborn infants with birth weight ≥ 2.500 g and gestational age ≥ 37 weeks were considered eligible for the study. exclusion criteria: * hiv-positive mothers * congenital malformation * infants referred to intensive care unit * multiple pregnancy.

Keywords: health plan implementation feeding and eating disorders of childhood breastfeeding complementary feeding morbidity anemia public policy
effects of coffee consumption on glucose metabolism

Conditions: Healthy

Summary: epidemiological studies have shown an inverse association between coffee consumption and risk of type 2 diabetes mellitus (t2dm). however the experimental studies that analysed the mechanisms are limited. this project aims to assess the effects of coffee consumption on glucose metabolism, using stable isotope tracer (13c-glucose) to explain the possible metabolic mechanisms involved on the reduced risk for t2dm.

this is a crossover randomized clinical trial that has been studying 14 male healthy young adults, who were enrolled five treatments: coffee with sugar, coffee without sugar, decaffeinated coffee without sugar and two controls (water with and without sugar). the stable isotope minimal model protocol with oral glucose administration (oral dose intravenous label experiment - odile) was performed. the use of odile methodology permits separation of the glucose absorbed and removed from the circulation increasing the accuracy and the effectiveness of glucose uptake and insulin sensitivity (bluck et al., 2006).

Eligibility criteria:
inclusion criteria: * male healthy young adults (18 - 50 years old); * body mass index (bmi) between 18.5 - 28.0 kg/m²; * no weight changes (≥ 5 kg) in the last 3 months; * not take any pills/drugs that alter metabolism, appetite and sleep; * not have sleep disorders; * not have donated blood in the last 3 months; * regular breakfast consumption (≥100 kcal ingested up to 2 hours after waking ≥4x/week); * being a habitual coffee consumer (≥100ml ≥5x/week). exclusion criteria: * diagnosis of anemia, metabolic and heart diseases; * previous sudden fainting and convulsions; * any drugs and tobacco consumption; * consumption of more than 500mg of caffeine / day (5 cups of coffee, tea and cola soft drinks).

Keywords: coffee glucose insulin diabetes type 2 diabetes mellitus
near-infrared autofluorescence with pth test strip as an sop of parathyroid in thyroid surgery

Conditions: Thyroid Cancer; Hypoparathyroidism; Optical Imaging

Summary: this is a prospective study aiming to establish near-infrared autofluorescence technology and pth test strip as a standardized process for finding and identifying parathyroid glands in thyroid surgery.

this is a prospective study aiming to establish near-infrared autofluorescence technology and pth test strip as a standardized process for finding and identifying parathyroid glands in thyroid surgery. nifra first photographed all specimens from thyroidectomy with or without central neck dissection, and positive tissues under near-infrared light were recorded in a neck map. then, a senior surgeon examined the parathyroid glands with the naked eye. these suspicious tissues were then identified with the pth test strip as a gold standard. finally, the parathyroid glands discovered during the operation that could not be preserved in situ were excluded from the procedure comparison and classified as strategic parathyroid transplantation.

Eligibility criteria:
inclusion criteria: * patients diagnosed with thyroid cancer by fna * scheduled for surgical treatment exclusion criteria: * patients with papillary thyroid microcarcinoma who ready for radiofrequency ablation or survival monitoring

Keywords: pth test strip near-infrared autofluorescence (niraf) thyroid cancer
a survey evaluating prevalence, severity and associated factors in east asian women with moderate-to-severe menopause-related vasomotor symptoms (mr-vms)

Conditions: Menopause

Summary: the purpose of this study is to estimate the prevalence of vasomotor symptoms (vms) and prevalence of moderate to severe vms in peri-menopausal women and post-menopausal women aged 40-65 in east asia (china, south korea and taiwan) and the proportion of the following subpopulations: hormone replacement therapy (hrt)-eligible and willing to take hrt; hrt-eligible and hrt-averse (i.e. not willing to take hrt); hrt-ineligible due to contra-indications/high-risk; and hrt-stoppers. the study will also assess health related quality of life (hrqol) and vms related productivity loss among perimenopausal and post-menopausal women with moderate-to-severe mr-vms and the respondents' attitudes toward prescription treatments.

the study will recruit women of 40-65 years old from an established consumer panel in china, south korea, and taiwan. women who meet the inclusion criteria for part i will be recruited to sign the informed consent form (icf) and participate in part i of the survey. based on the information collected in part i of the survey, peri- and post-menopausal women who meet the inclusion criteria for part ii will be directed to part ii of the survey. the survey will be terminated for women who do not meet the inclusion criteria for part ii.

Eligibility criteria:
inclusion criteria (part i): * evidence of peri-menopause (changes in the regular period in terms of irregularity in the length of the period, the time between periods, and the level of flow), or * evidence of post-menopause (spontaneous amenorrhea over 12 months) inclusion criteria (part ii): * presence of moderate-to-severe menopause-related vasomotor symptoms (mr-vms); moderate: sensation of heat with sweating, able to continue activity; severe: sensation of heat with sweating, causing cessation of activity) exclusion criteria (part i): * no evidence of peri-menopause or post-menopause, or * women who are currently participating or have participated in menopause-related vasomotor symptoms (mr-vms) clinical trials exclusion criteria (part ii): * subjects who are treated with tamoxifen, aromatase inhibitors or gonadotropin-releasing hormone (gnrh) agonists/antagonists for cancer or any other medical condition, or * subjects who have mild menopause-related vasomotor symptoms (mr-vms) only

Keywords: peri-menopausal hormone replacement therapy menopause vms post-menopausal menopausal vasomotor symptoms hrt
prevention of upper gastrointestinal hemorrhage using albis® in the patients of locally advanced pancreatic cancer who underwent concurrent chemoradiotherapy

Conditions: Pancreatic Ductal Adenocarcinoma

Summary: pancreatic ductal adenocarcinoma is the fourth cause of death in the western world. about 40% of pancreatic cancer patients were diagnosed as locally advanced unresectable status without distant metastasis. concurrent chemoradiotherapy (ccrt) was a reasonable treatment modality for locally advanced pancreatic cancer. however, several adverse events of chemoradiation could lead unfavorable treatment results, which included unique gastrointestinal (gi) toxicities, such as ulcer and hemorrhage in the stomach and duodenum that are included in the radiation field. according to the study in the investigators hospital, 45% of locally advanced pancreatic cancer patients treated with ccrt suffered from gi ulcers, and among them, 65% of the patients experienced the significant hemorrhage events. although these gi toxicities, the studies for radioprotective agents were limited. albis® is a newly developed drug comprised of ranitidine, bismuth and sucralfate. the investigators will investigate the radioprotective effect of albis® for locally advanced pancreatic cancer patients treated with ccrt.


Eligibility criteria:
inclusion criteria: * older than 20 years old and younger than 80 years old * pathologically confirmed pancreatic ductal adenocarcinoma (metastatic or locally advanced stage) * ecog performance status ≤2 * scheduled fot concurrent chemoradiation * adequate liver function (total bilirubin \< 1.5 x the upper limits of normal (uln), ast and alt \<3 x unl, and alkaline phosphatases \< 3 x uln or \< 5 x uln in case of liver involvement) * adequate bm function (wbc ≥ 3,500/µl, absolute neutrophil cell count ≥ 1,500 /µl, platelet count ≥ 100,000/µl) * not remarkable coagulation profile (pt \< 1.5 international normalized ratio(inr), aptt \<35 sec) * subjects who given written informed consent after being given a full description of the study exclusion criteria: * coexisting of other malignancies within 5 years, except squamous cell carcinoma and basal cell carcinoma of the skin * evidence of distant metastasis, such as liver, peritoneum and brain * history of receiving the chemoradiation for pancreatic cancer in the other hospital * history of receiving the operation which affect the anatomy of upper gastrointestinal tract * any trouble for examination of upper endoscopy * evidence of gi ulcers (a1\~h2) on endoscopy before start of chemoradiotherapy. * use of aspirin, anti-platelet agent, anticoagulation agent, nsaids, or glucocorticoid within 1 week or enable to stop the administration (including start during chemoradiation) * use of ppi, histamine-2 receptor antagonist, antacid, prostaglandin, sucralfate within 2 weeks or enable to stop the administration * patients who are unwilling or unable to provide informed consent, such as those with psychiatric problem, drug abuse or alcoholism

Keywords: pancreatic cancer chemoradiotherapy gastrointestinal toxicity albis